U.S. appeals court sides with Catalyst, calling FDA approval of Jacobus' Ruzurgi 'arbitrary,' 'capricious' and unlawful - Fierce Pharma
A U.S. appeals court ruled that the FDA's approval of Jacobus' Ruzurgi was arbitrary and unlawful, siding with Catalyst. This may affect drug approval processes and competitive exclusivity for branded drug makers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Within 30 days to adjust regulatory strategies.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The court decision challenges FDA's approval of a competitor drug, potentially altering market exclusivity and approval standards for similar products.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers
What you must do
Review your drug approval strategies and monitor FDA responses to this ruling; assess impact on pending applications or exclusivity claims.
Deadline
Within 30 days to adjust regulatory strategies.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)